This is a randomized, double-blind, placebo-controlled, parallel groups, multicenter pivotal study assessing the efficacy and safety of 15 mg BID of SER150 in well-controlled adult T2D participants with stable concomitant medications, diabetic kidney disease (DKD) and macroalbuminuria in treatment with an ACEI or an ARB.~The randomized treatment period will be 24 weeks followed by a 4-weeks follow-up.
This study is to assess the efficacy, safety and pharmacokinetic (PK) of SER150 administered for 24 weeks as a 15 mg twice a day (BID) dose in participants with type 2 diabetes (T2D) and macroalbuminuria in treatment with either an angiotensin converting enzyme inhibitor (ACEI) or an angiotensin receptor antagonist (ARB).